In order to implement the spirit of the Central Economic Work Conference and the Central Financial Work Conference, adhere to the investor-oriented concept, promote continuous optimization of operation, standardized governance, and active return to investors, also contribute to boosting confidence, stabilizing the capital market, and promoting high-quality economic development, Shanghai United Imaging Healthcare Co., Ltd. (referred to as "United Imaging" or the "Company") has formulated the Corporate Value ...

中信证券股份有限公司、中国国际金融股份有限公司 关于上海联影医疗科技股份有限公司 调整部分募投项目内部投资结构并延期的核查意见 中信证券股份有限公司（以下简称"中信证券"、"保荐机构"）、中国国 际金融股份有限公司（以下简称"中金公司"、"保荐机构"）为上海联影医疗 科技股份有限公司（以下简称"公司"、"联影医疗"）首次公开发行股票并上 市的保荐机构。根据《证券发行上市保荐业务管理办法》、《上海证券交易所科 创板股票上市规则》、《科创板上市公司持续监管办法（试行）》及《上市公司 监管指引第 2 号——上市公司募集资金管理和使用的监管要求》等有关规定，对 联影医疗调整部分募集资金投资项目（以下简称"募投项目"）内部投资结构并 延期的事项进行了核查，并出具核查意见如下： 一、募集资金的基本情况 根据中国证监会核发的《关于同意上海联影医疗科技股份有限公司首次公开 发行股票注册的批复》（证监许可[2022]1327 号），联影医疗获准向社会公开发 行人民币普通股（A 股）10,000 万股，发行价格为 109.88 元/股，募集资金总额 1,098,800 万元。公司募集资金总额扣除所有股票发行费用（包括不含增值税承 ...

证券代码： 688271 证券简称： 联影医疗 公告编号： 2024-013 上海联影医疗科技股份有限公司 关于使用部分闲置募集资金进行现金管理的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 上海联影医疗科技股份有限公司（以下简称"公司"或"联影医疗"）于 2024 年 4 月 25 日召开第二届董事会第六次会议、第二届监事会第三次会议，审议通 过了《关于使用部分闲置募集资金进行现金管理的议案》，同意公司在确保募集 资金投资项目所需资金充足和保证募集资金安全的前提下，合计使用不超过人民 币 520,000 万元(含本数)的闲置募集资金进行现金管理，用于购买安全性高、流 动性好、有保本约定的投资产品，在上述额度范围内，资金可以滚动使用，使用 期限自公司本次董事会审议通过之日起 12 个月内有效。董事会授权公司董事长 或董事长授权人员在上述额度范围及有效期内行使投资决策权并签署相关合同 文件，具体事项由公司财务部负责组织实施，该事项无需提交股东大会审议。 根据中国证监会核发的《关于同意上海联影医疗科技股份有限公司首次公 ...

上海联影医疗科技股份有限公司 2023 年度内部控制审计报告 普华永道 内部控制审计报告 普华永道中天特审字(2024)第 2095 号 (第一页,共二页) 按照《企业内部控制基本规范》、《企业内部控制应用指引》、《企业内部控制评价 指引》的规定,建立健全和有效实施内部控制,并评价其有效性是联影医疗董事 会的责任。 rí 注册会计师的责任 我们的责任是在实施审计工作的基础上,对财务报告内部控制的有效性发表审计 意见,并对注意到的非财务报告内部控制的重大缺陷进行披露。 ní 内部控制的固有局限性 内部控制具有固有局限性,存在不能防止和发现错报的可能性。此外,由于情况 的变化可能导致内部控制变得不恰当,或对控制政策和程序遵循的程度降低,根 据内部控制审计结果推测未来内部控制的有效性具有一定风险。 普华永道中天会计师事务所(特殊普通合伙) 中国上海市黄浦区湖滨路202号领展企业广场2座普华永道中心11楼 邮编200021 总机:+86 (21) 2323 8888,传真:+86 (21) 2323 8800, www.pwccn.com 普华永道 上海联影医疗科技股份有限公司全体股东: 按照《企业内部控制审计指引》 ...

证券代码： 688271 证券简称： 联影医疗 公告编号： 2024-016 上海联影医疗科技股份有限公司 关于增加 2024 年度日常关联交易预计的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、日常关联交易概述 （一）日常关联交易履行的审议程序 上海联影医疗科技股份有限公司（以下简称"公司"或"联影医疗"）于 2024 年 4 月 25 日召开第二届董事会第六次会议审议通过了《关于增加 2024 年度日常 关联交易预计的议案》，表决结果为：赞成 9 票，无反对票，无弃权票。本次日 常关联交易为向关联方深圳市联新移动医疗科技有限公司销售医学影像设备和 配件等，预计增加金额人民币 7,700 万元。据《上海证券交易所科创板股票上市 规则》《上海联影医疗科技股份有限公司章程》等相关规定,本议案无需提交股东 大会审议。 独立董事专门会议审核意见：公司本次增加 2024 年度日常关联交易预计符 合公司经营需要，定价遵循了公平、合理的原则，不存在损害公司及其他股东特 是否需要提交股东大会审议：否 日常关联 ...

第二届董事会独立董事第一次专门会议决议 上海联影医疗科技股份有限公司（以下简称"公司"）第二届董事会独立董 事第一次专门会议于 2024 年 4 月 25 日以通讯方式召开，本次会议的通知于 2024 年4月15日通过书面方式送达各位独立董事，会议通知中包括会议的相关材料， 同时列明了会议召开的时间、地点、内容及方式。本次会议应参加独立董事 3 名， 实际参加独立董事 3 名，全体独立董事共同推举王少飞先生主持本次会议，本次 会议的召集、召开方式符合《中华人民共和国公司法》等法律、行政法规、部门 规章、规范性文件和《上海联影医疗科技股份有限公司章程》的规定，会议召开 的方式、程序及做出的决议合法有效。 一、审议通过《关于推举第二届董事会独立董事专门会议召集人的议案》 经过半数以上独立董事推举，公司第二届董事会独立董事专门会议召集人由 独立董事王少飞先生担任，任期与第二届董事会任期相同。 表决结果：3 票同意、0 票反对、0 票弃权。 二、审议通过《关于公司增加 2024 年度日常关联交易预计的议案》 经全体与会独立董事审议：公司本次增加 2024 年度日常关联交易预计符合 公司经营需要，定价遵循了公平、合理的 ...

| 会议名称 | | 召开日期 | 会议内容 | | --- | --- | --- | --- | | 第一届董事会 | 2023 | 2023.4.26 | 审计委员会经过充分沟通讨论，一致审议通过《关于公司 2022 年年度报告及摘要的议案》、《关于续聘 2023 年度会计 | | 年第一次会议 | | | | | | | | 师事务所的议案》、《关于公司 2023 年第一季度报告的议案》。 | | 第一届董事会 | 2023 | 2023.8.18 | 审计委员会经过充分沟通讨论，一致审议通过《关于公司 | | 年第二次会议 | | | 2023 年半年度报告及摘要的议案》。 | | 第二届董事会 | 2023 | 2023.10.27 | 审计委员会经过充分沟通讨论，一致审议通过《关于公司 | | 年第一次会议 | | | 2023 年第三季度报告的议案》。 | | 第二届董事会 | 2023 | 2023.12.28 | 审计委员会经过充分沟通讨论，一致审议通过《关于 2024 | | 年第二次会议 | | | 年度日常关联交易预计的议案》。 | 三、董事会审计委员会年度履职情况 （一）审核与评估 ...

一、会计师事务所的基本情况 普华永道中天前身为 1993 年 3 月 28 日成立的普华大华会计师事务所，经批 准于 2000 年 6 月更名为普华永道中天会计师事务所有限公司；经 2012 年 12 月 24 日财政部财会函[2012]52 号批准，于 2013 年 1 月 18 日转制为普华永道中天 会计师事务所（特殊普通合伙），注册地址为中国（上海）自由贸易试验区陆家 嘴环路 1318 号星展银行大厦 507 单元 01 室。普华永道中天是普华永道国际网络 成员机构，拥有会计师事务所执业证书，具备从事 H 股企业审计业务的资质，同 时也是原经财政部和证监会批准的具有证券期货相关业务资格的会计师事务所。 此外，普华永道中天也在 US PCAOB（美国公众公司会计监督委员会）及 UK FRC （英国财务汇报局）注册从事相关审计业务。 普华永道中天的首席合伙人为李丹。截至 2023 年 12 月 31 日，普华永道中 天合伙人数为 291 人，注册会计师人数为 1,710 余人，其中自 2013 年起签署过 证券服务业务审计报告的注册会计师人数为 383 人。普华永道中天经审计的最近 一个会计年度（2022 ...

Financial Performance and Dividends - The company plans to distribute a cash dividend of RMB 2.50 per 10 shares, totaling RMB 204,860,291.75 (including tax), with a total cash dividend payout of RMB 689,379,549.53 for 2023, accounting for 34.92% of the net profit attributable to shareholders[8] - Revenue for 2023 reached RMB 11.41 billion, a 23.52% increase compared to 2022[23] - Net profit attributable to shareholders in 2023 was RMB 1.97 billion, up 19.21% year-over-year[23] - Operating cash flow in 2023 was RMB 132.51 million, a significant decrease of 80.59% compared to 2022[23] - Total assets at the end of 2023 stood at RMB 25.34 billion, a 4.68% increase from the previous year[23] - The company's equity attributable to shareholders increased by 7.91% to RMB 18.87 billion at the end of 2023[23] - Basic earnings per share increased by 9.59% to 2.40 yuan per share in 2023 compared to 2022[24] - Net profit attributable to the parent company increased by 19.21% to 19.74 billion yuan in 2023[25] - R&D investment accounted for 16.81% of operating income, an increase of 0.94 percentage points from 2022[25] - Total operating revenue reached 114.11 billion yuan in 2023, a year-on-year increase of 23.52%[25] - Net profit attributable to the parent company after deducting non-recurring gains and losses increased by 25.38% to 16.65 billion yuan in 2023[25] - Total assets at the end of 2023 were 253.36 billion yuan, a year-on-year increase of 4.68%[25] - Equity attributable to the parent company at the end of 2023 was 188.66 billion yuan, a year-on-year increase of 7.91%[25] - Operating cash flow in the fourth quarter of 2023 was 974.60 million yuan, a significant improvement compared to previous quarters[29] - Government subsidies received in 2023 amounted to 235.42 million yuan, a decrease from 335.56 million yuan in 2022[30] - Revenue increased by 23.52% to RMB 11,410,765,602.39 compared to the previous year[115] - Operating costs rose by 23.24% to RMB 5,878,580,949.27[115] - R&D expenses grew by 32.33% to RMB 1,728,541,428.81 due to increased investment in research and development[115] - Sales expenses increased by 33.28% to RMB 1,769,512,581.90, driven by higher sales personnel costs and travel expenses[115] - Net cash flow from operating activities decreased by 80.59% to RMB 132,511,079.76[115] - The gross profit margin for the medical device industry increased by 0.12 percentage points to 48.99%[117] - Revenue from medical imaging diagnostic and radiotherapy equipment sales grew by 21.10% to RMB 9,927,400,522.47[117] - Revenue from maintenance services increased by 42.78% to RMB 1,069,374,958.28, with a gross profit margin increase of 5.93 percentage points[117] - Software revenue surged by 124.85% to RMB 174,468,152.21, with a gross profit margin increase of 12.82 percentage points[117] - Domestic revenue accounted for RMB 9,512,035,184.75, a 19.70% increase from the previous year[117] - Total revenue from medical imaging and radiotherapy equipment sales reached 9.927 billion yuan, a year-on-year increase of 21.10%[119] - MR equipment sales revenue increased by 58.50% year-on-year to 3.279 billion yuan[119] - XR equipment sales revenue grew by 32.83% year-on-year to 760.18 million yuan[119] - Maintenance service revenue increased by 42.78% year-on-year to 1.069 billion yuan[119] - Software revenue surged by 124.85% year-on-year to 174.47 million yuan[119] - Domestic revenue grew by 19.70% to 9.512 billion yuan, while overseas revenue increased by 53.97% to 1.659 billion yuan[119] - Direct material costs accounted for 89.08% of total costs, increasing by 25.11% year-on-year[122] - Direct labor costs rose by 40.74% year-on-year, with equipment-related labor costs increasing by 54.79%[123] - Top five customers accounted for 9.91% of total sales, with no sales to related parties[125] - The top 5 suppliers accounted for 7.27% of the total annual procurement amount, with the largest supplier contributing 31,651.84 thousand RMB, representing 2.00% of the total procurement[129] - Sales expenses increased by 33.28% to 1,769,512,581.90 RMB, driven by higher sales personnel costs and travel/conference expenses[130] - R&D expenses rose by 32.33% to 1,728,541,428.81 RMB due to increased investment in R&D materials and personnel costs[130] - Net cash flow from operating activities decreased by 80.59% to 132,511,079.76 RMB, primarily due to increased raw material procurement, labor costs, and tax payments[131] - Net cash flow from financing activities dropped by 106.17% to -662,170,739.78 RMB, mainly due to the completion of the IPO in the previous year and the implementation of share repurchases and dividend distributions[132] - Accounts receivable increased by 60.34% to 3,227,657,250.54 RMB, accounting for 12.74% of total assets, driven by higher sales[133] - Overseas assets amounted to 1,390,810,078.55 RMB, representing 5.49% of total assets[135] - The company invested 52,591,941.34 RMB in equity investments during the reporting period, a 26,195.97% increase compared to the previous year[138] - The next-generation R&D product project has a total estimated investment of 6.168 billion RMB, with a progress rate of 21.27%[139] Technological Innovation and R&D - The company aims to accelerate the application of new productive forces by integrating AI and information technology with innovative imaging, radiotherapy, and interventional equipment[4] - The company is committed to advancing technological innovation, including AI, 5G, and IoT, to enhance the integration of high-end medical equipment and develop globally competitive super equipment[2] - The company is exploring the application of circular economy models in the medical industry to reduce resource consumption and environmental pollution throughout the product lifecycle[2] - The company emphasizes the importance of deep collaboration between industry, academia, and medical institutions to drive innovation and solve broader medical challenges[2] - The company highlights the growth potential of China's healthcare industry, which is transitioning to a high-quality development phase, creating opportunities for digital and AI-driven medical solutions[3] - The company successfully launched multiple innovative products in 2023, further consolidating its leading market position[33] - R&D investment accounted for 16.81% of total revenue, an increase of 0.94 percentage points year-over-year[34] - Over 120 products have been launched, with 20+ new hardware and software products receiving NMPA registration in China[34] - Cumulative patent applications exceeded 9,900, with over 80% being invention patents, and over 5,100 intellectual property authorizations, including more than 3,000 invention patents[35] - The company's total R&D investment in 2023 reached 1,918,617,388.39 yuan, a 30.84% increase compared to the previous year[87] - R&D investment as a percentage of revenue increased to 16.81%, up 0.94 percentage points from the previous year[87] - The company has accumulated 9,944 intellectual property applications, with 5,160 granted, including 6,953 invention patent applications and 3,029 granted[84][85] - In 2023, the company added 1,226 new intellectual property applications, with 967 granted, including 956 invention patent applications and 729 granted[84][85] - The company has 45 ongoing R&D projects with a total planned investment of 4,388 million yuan, and a cumulative investment of 3,016.16 million yuan by the end of 2023[89][90] - The MR R&D project series has a total planned investment of 1,040 million yuan, with a cumulative investment of 959.9 million yuan by the end of 2023[89] - The CT R&D project series has a total planned investment of 2,500 million yuan, with a cumulative investment of 2,053.03 million yuan by the end of 2023[89] - The RT R&D project series has a total planned investment of 3,650 million yuan, with a cumulative investment of 2,628.62 million yuan by the end of 2023[89] - The software R&D project series has a total planned investment of 2,450 million yuan, with a cumulative investment of 1,395.9 million yuan by the end of 2023[89] - The XR R&D project series has a total planned investment of 1,500 million yuan, with a cumulative investment of 1,130.58 million yuan by the end of 2023[89] - The number of R&D personnel decreased from 3,088 to 2,956, accounting for 39.73% of the total workforce, down from 42.29% in the previous period[91] - Total R&D personnel compensation increased to RMB 131,448.48 thousand, with an average salary of RMB 44.47 thousand, up from RMB 34.25 thousand[91] - The company has a comprehensive product portfolio covering MR, CT, XR, PET/CT, PET/MR, and RT, with several industry-first products such as the uEXPLORER Total-body PET/CT and uMR Jupiter 5T[93][94] - The company has established a vertical R&D system and a platform-based R&D model, enabling self-developed core components and efficient product iteration[95] - As of the reporting period, the company had 2,956 R&D personnel, representing 39.73% of the total workforce[96] - The company has filed over 9,900 intellectual property applications, with over 80% being invention patents, and has been granted over 5,100 intellectual property rights, including over 3,000 invention patents[97] - The company's R&D model follows medical device regulatory requirements and ISO quality system standards, with a structured product development process[62] - The company maintains a safety stock for mass-produced materials and collaborates with suppliers for non-mass-produced and long-lead-time materials to ensure timely supply[63] - The company uses information technology to build an intelligent production system, improving efficiency and reducing costs[64] - The company has developed the industry's first 75cm large-aperture 3.0T and 5.0T whole-body MRI products, as well as the first domestically produced 3.0T MR and 9.4T animal MR products[70] - The company's self-developed spatiotemporal detector supports a minimum slice thickness of 0.5mm and is used in its CT series products[71] - The company has developed an AI-based full-model iterative reconstruction algorithm for CT products, which maximizes dose reduction while meeting clinical diagnostic requirements[71] - The company's high-resolution detector technology in molecular imaging can effectively improve image quality, scanning speed, and reduce scanning dose[71] - The company's 6MV accelerator tube achieves a maximum dose rate of 600MU/min@1m in flattened mode and 1400MU/min@1m in unflattened mode, leading the industry[71] - The company's product line covers high-end medical imaging diagnostic products and radiotherapy products, achieving an integrated diagnosis and treatment layout[72] - The company is one of the few in the industry capable of designing and manufacturing long-axis PET products[71] - The company's dynamic multi-leaf collimator technology enables efficient and precise volumetric intensity-modulated radiation therapy, reducing radiation dose to normal tissues[71] - The company is a major player in the Chinese medical imaging and radiotherapy equipment market, ranking second in CT market share, third in MR market share, and first in PET/CT and PET/MR market share[73] - In the CT market, the company ranks first in market share for 40-row and below CTs, first for 41-63 row CTs, and third for 64-row and above CTs[73] - In the MR market, the company ranks second in market share for 1.5T and below superconducting MRs, third for 3.0T MRs, and first for 3.0T and above ultra-high-field MRs[73] - The company holds the top market share in diagnostic XR products (including fixed DR, mobile DR, and breast DR) in China, with first place in fixed DR and breast DR, and second place in mobile DR[73] - In the radiotherapy equipment market, the company ranks third in market share for RT products[73] - The company is one of the few global companies with core technology and complete machine production capabilities for 5.0T and above MR systems[75] - The company has mastered key technologies such as sub-millimeter unit resolution, depth effect recognition and correction, and online scatter effect recovery for animal PET/CT systems[75] - The company's RT products feature image-guided radiotherapy, enabling precise targeting of tumors and adaptive treatment planning based on tumor changes[75] - The company is developing high-sensitivity acquisition, molecular imaging, and fast imaging technologies for preclinical MRI systems[75] - The company is advancing digital PET/CT technology using Silicon Photomultiplier (SiPM) to improve spatial resolution, sensitivity, and count rate characteristics[75] - The company has mastered the core technology of 5.0T and above high-field human superconducting magnets, achieving a 75cm large patient aperture 3.0T superconducting magnet for the first time[76] - The gradient strength of the high-performance gradient coil design and production technology ranges from 33mT/m to 120mT/m, with a gradient switching speed of 125T/m/s to 220T/m/s, leading the industry[76] - The full digital megawatt-level gradient power amplifier (GPA) technology covers a power range from 0.7 megawatts to 3.5 megawatts, achieving industry-leading levels[76] - The full digital radio frequency power amplifier (RFPA) technology uses all-solid-state power amplification and high-density, high-integration structural optimization to reduce size and cost[76] - The high-field multi-channel RF transmission technology enables independent control of multiple channels, improving RF transmission magnetic field uniformity[76] - The RF reception coil design and production technology covers all body parts with high-channel dedicated reception coils, leading the industry[76] - The distributed spectrometer and fiber optic digital transmission technology achieves industry-leading levels in high reception channel count and signal stability[76] - The magnetic resonance rapid imaging technology platform achieves 0.5 seconds per phase rapid dynamic high-definition imaging, a first in the industry[76] - The magnetic resonance automation scanning technology enables intelligent scanning of various body parts, including the head, heart, spine, and abdomen[76] - The magnetic resonance advanced application and post-processing technology includes industry-first advanced application technologies such as complex domain diffusion reconstruction and multi-echo advanced magnetic susceptibility weighted imaging[76] - The company's full-view cone-beam CT reconstruction technology expands the reconstruction field of view to 431mm, achieving full abdominal coverage[78] - The digital light guide PET detector design achieves industry-leading sensitivity and spatial resolution using SiPM and LYSO crystals[79] - The company's high-precision PET detector calibration technology improves signal processing accuracy and image quality, maintaining system stability[79] - The parallel image reconstruction method based on GPU acceleration significantly enhances computational speed and quantitative accuracy[79] - The AI-based reconstruction algorithm reduces image noise, improves image quality, and shortens scan time[79] - The AI-based attenuation correction technology includes body skeletal information, significantly improving image quality and quantitative accuracy[79] - The motion artifact reduction technology effectively minimizes PET image artifacts caused by respiratory and head movements[79] - The tumor analysis technology supports PERCIST and RECIST standards, enabling rapid and accurate diagnosis of tumor diseases[79] - The parameter imaging and analysis technology provides quantitative drug metabolism analysis based on multiple models[79] - The company's multi-scale image enhancement and equalization technology in static DR imaging highlights lesion locations[78] - High dose rate dual-beam accelerator technology achieves a maximum output of over 1400 MU/min in FFF mode, significantly improving treatment efficiency[80] - The precision dose control system achieves a minimum control dose follow-up accuracy of less than 0.1 MU and long-term stability of less than 1%[80] - The dynamic multi-leaf collimator system achieves a repeat positioning accuracy of less than 0.5mm and supports real-time dynamic control[80] - The integrated CT imaging technology enables precise registration before treatment and real-time monitoring of dose distribution during treatment[80] - The high-precision treatment bed achieves the longest motion range, highest stiffness, and smallest error in the industry[80] - The Monte Carlo dose calculation algorithm achieves routine plan calculations in less than 1 minute[80] - The cross-modal software workflow technology improves clinical efficiency and reduces learning costs for end-users[81] - The 3D medical imaging visualization engine technology achieves ultra-high resolution and real-time rendering with zero waiting time[81] - The complex electromagnetic environment hardware circuit design technology supports high-speed data acquisition at 39*4Gps in a 0.25s rotation[81] - The high-precision cooling temperature control technology achieves precise temperature control for core components and system-level temperature management[82] Global Expansion and Subsidiaries - United Imaging Healthcare has a wide range of subsidiaries globally, including in the UK, Hong Kong, UAE, Korea, Poland, Japan, Malaysia, South Africa, Morocco, Kazakhstan, Singapore, Colombia, Indonesia, and the US[13] - The company has significant holdings in subsidiaries such as UIH America, Inc., United Imaging Healthcare Japan, and United Imaging Healthcare (Australia & New Zealand) Pty Ltd[13] - United Imaging Healthcare has strategic partnerships with entities like Shenzhen High-Performance Medical Devices National Research Institute Co., Ltd. and Wuhan Zhongke Medical Technology Industrial Technology Research Institute Co., Ltd.[13] - The company's subsidiaries are involved in

Financial Performance - The company's operating revenue for Q1 2024 was ¥2,350,478,362.11, representing a year-on-year increase of 6.22%[4] - The net profit attributable to shareholders was ¥363,297,720.56, reflecting a growth of 10.20% compared to the same period last year[4] - The net profit after deducting non-recurring gains and losses was ¥300,194,937.03, an increase of 8.52% year-on-year[4] - Total operating revenue for Q1 2024 reached ¥2,350,478,362.11, an increase of 6.25% compared to ¥2,212,870,463.39 in Q1 2023[19] - Net profit for Q1 2024 was ¥361,942,371.76, compared to ¥325,526,611.76 in Q1 2023, representing a growth of 11.16%[21] - Total comprehensive income for Q1 2024 reached ¥362,987,690.02, an increase from ¥320,718,943.78 in Q1 2023, representing a growth of approximately 13.2%[22] - Basic and diluted earnings per share for Q1 2024 were both ¥0.44, up from ¥0.40 in Q1 2023, indicating a 10% increase[22] Research and Development - Research and development expenses totaled ¥506,949,927.30, accounting for 21.57% of operating revenue, which is an increase of 2.12 percentage points[6] - Research and development expenses for Q1 2024 amounted to ¥419,681,857.09, slightly increasing from ¥412,457,903.29 in Q1 2023[19] Assets and Liabilities - The total assets at the end of the reporting period were ¥25,347,749,297.37, a slight increase of 0.05% from the end of the previous year[6] - The company's current assets totaled RMB 19,770,733,478.26, down from RMB 20,227,806,280.02 in the previous period[16] - The total liabilities decreased to ¥6,079,087,771.00 in Q1 2024 from ¥6,454,724,356.28 in Q1 2023, a reduction of approximately 5.80%[18] - The total equity attributable to shareholders increased to ¥19,225,030,179.95 in Q1 2024 from ¥18,866,353,649.67 in Q1 2023, marking an increase of 1.90%[18] - The total non-current assets reached RMB 5,577,015,819.11, up from RMB 5,108,334,041.94[16] Cash Flow - The net cash flow from operating activities was -¥657,050,656.93, attributed to a decrease in sales receipts[4][8] - Cash inflow from operating activities totaled ¥2,077,775,422.40, down from ¥2,610,056,376.38 in the previous year, reflecting a decrease of about 20.4%[23] - Net cash outflow from operating activities was ¥657,050,656.93, compared to a net outflow of ¥313,565,330.56 in Q1 2023, indicating a worsening cash flow situation[23] - Cash inflow from investment activities amounted to ¥3,218,668,313.04, significantly higher than ¥2,011,147,671.24 in Q1 2023, marking an increase of approximately 60%[24] - Net cash outflow from investment activities was ¥1,123,792,938.39, an improvement from the outflow of ¥1,470,765,954.23 in the same period last year[24] - Cash inflow from financing activities was ¥7,800,000.00, up from ¥4,200,000.00 in Q1 2023, showing an increase of 85.7%[24] - The net cash outflow from financing activities was ¥52,965,585.80, compared to an outflow of ¥10,893,128.25 in Q1 2023, indicating a larger cash drain[24] - The ending balance of cash and cash equivalents was ¥5,695,446,410.92, down from ¥7,826,631,778.09 at the end of Q1 2023, a decrease of approximately 27.2%[24] Shareholder Information - The top shareholder, 联影医疗技术集团有限公司, holds 20.33% of the shares, totaling 167,550,968 shares[10] - The company reported a total of 16,859 common shareholders at the end of the reporting period[10] - The company has not reported any significant changes in its shareholder structure or related party transactions during the reporting period[12] Other Information - The company received government subsidies amounting to ¥45,913,640.25, which are closely related to its normal business operations[7] - There are no other important reminders regarding the company's operational situation during the reporting period[14] - The company did not apply new accounting standards for the first quarter of 2024[25]